ValueInvesting

I find and buy undervalued stocks. Tweets are my own opinion.

[ValueInvesting @ValueInvestor92]

@HOThomasWPhelps @semodough Agreed, I think crvs has a pretty good chance in that trial as well

[ValueInvesting @ValueInvestor92]

@HOThomasWPhelps @semodough It doesn’t look like they are modeling phase 1 of soquelitinib in solid tumors either?

[ValueInvesting @ValueInvestor92]

@HOThomasWPhelps @Kennydoesbio That’s a good point, thanks for sharing

[ValueInvesting @ValueInvestor92]

@JamesEKrause @semodough I think there is an untapped markets of patients unwilling to take an injection, that would take a pill. If AD was a life threatening disease, I think they would choose the most efficacious regardless of how it’s administered. But I think even half the efficacy is a big win

[ValueInvesting @ValueInvestor92]

@HOThomasWPhelps @wjhuber5 Agreed, great points

[ValueInvesting @ValueInvestor92]

@HOThomasWPhelps @wjhuber5 Assuming fully diluted shares of 84m (includes warrants), CRVS market cap is still only $530m. Still extremely cheap for where they’re at. If I recall correctly, DICE and Principia were worth well over $1bn during phase 1 trials in autoimmune

[ValueInvesting @ValueInvestor92]

@HOThomasWPhelps @LeeBiotechology Btw Richard Miller was also a founder of Principia

[ValueInvesting @ValueInvestor92]

@HOThomasWPhelps That’s great to know. You can see from the slides from one of their older presentations, by day 28 one of the dogs was almost completed cleared of AD

[ValueInvesting @ValueInvestor92]

@HOThomasWPhelps Exactly, there is something there to cure 5/5 dogs

[ValueInvesting @ValueInvestor92]

@HOThomasWPhelps Same man. Really excited to see how SQL does with AD

[ValueInvesting @ValueInvestor92]

@AaronRosenblum5 @Kennydoesbio Agreed, needs to have a good safety profile

[ValueInvesting @ValueInvestor92]

@Kennydoesbio One thing you aren’t considering is that Dupixent is an injection. If CPI-818 is even half as effective, it’s a big win. Most people don’t prefer injections, especially for non fatal conditions

[ValueInvesting @ValueInvestor92]

@ConradEnge98050 @Andre_AGTC Great find

[ValueInvesting @ValueInvestor92]

@RobertSMBiotec @Pharmdca @ian_yuun62862 Believe total peak sales are estimated at $1.2bn. Not sure what valuation should be at this stage though, being that 1.2bn is estimated to be peak rev in 2030, which is 7 years from now.

[ValueInvesting @ValueInvestor92]

@ConradEnge98050 Curious to hear thoughts on valuation of these two drugs with phase 3 approval

[ValueInvesting @ValueInvestor92]

Long $CRVS- risk/reward ratio is too good to ignore.

- Strong data
- Strong Management (CEO was cofounder of PCYC which was bought out for $21bn)
- Ceo taking 90% of salary in stock over next few years hence incentive to avoid toxic dilution
- Relatively unnoticed (for now)

[ValueInvesting @ValueInvestor92]

@mtheory11bio Starting to get into bio, but I’d assume they’d be valued atleast 1-2x peak sales

[ValueInvesting @ValueInvestor92]

@LogarithmicDis @jesse_brodkin @smogcitygiraffe @lipa0902 @MoralOverdraft @FrankDavidCast8 @Adrian_H @Nemo_is_NoOne @Russell50k @PatricioMarceso @2020Fundamental @bluejaunt100 @ClicksAndHisses @jbeidel @DOJCrimDiv Insiders can’t buy before and shortly after earnings reports due to a blackout period. This is the likely reason they bought when they did, don’t be paranoid.

[ValueInvesting @ValueInvestor92]

@jesse_brodkin @smogcitygiraffe @lipa0902 @MoralOverdraft @FrankDavidCast8 @Adrian_H @Nemo_is_NoOne @Russell50k @PatricioMarceso @2020Fundamental @bluejaunt100 @ClicksAndHisses @jbeidel @DOJCrimDiv Actually the purchase was made on 8/12. I suggest doing research before making statements like that. $sava